drugset / Trial / NCT04888221
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
Phase 3
Active not recruiting
66 enrolled
Assistance Publique - Hôpitaux de Paris
Roche Chugai · collabRoche Pharma AG · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A French multicenter randomised and placebo-controlled study recruiting patients who present neurovascular involvement related to GCA (\> 60 years) with symptomatic (stroke) or asymptomatic forms. The aim of this study is to assess the efficacy of tocilizumab to induce complete remission of GCA with cerebrovascular involvement (clinical and biological) and absence of clinical and MRI ischemic stroke recurrence at 24 weeks.
Timeline
- Start
- 2021-09-24
- Primary completion
- 2025-01-29
- Completion
- 2025-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 162 mg | Subcutaneous |